Hims Hers profits are under scrutiny as the wellness platform’s expansion plans and Super Bowl ad expenditure raise concerns among investors. The company’s first-quarter profit forecast missed expectations, largely due to these strategic investments, exacerbating existing worries about legal and regulatory oversight of its weight-loss drug business.
Expansion Plans and Investor Anxiety
Shares of Hims & Hers (HIMS) experienced a decline in after-hours trading following the announcement. This move reflects growing apprehension regarding the company’s ambitious growth strategies amidst a challenging regulatory landscape. The stock’s after-hours performance compounds a 61% drop over the past year, highlighting the market’s sensitivity to the uncertainties surrounding Hims & Hers’ weight-loss drug offerings.
The company anticipates first-quarter revenue to range from $600 million to $625 million, falling short of analysts’ projected $653.1 million. Adjusted EBITDA is forecasted between $35 million and $55 million, significantly lower than the $82.3 million anticipated by analysts. CFO Yemi Okupe attributed the cautious outlook to changes in shipping patterns for weight-loss drugs, the cost of the Super Bowl advertisement, and investments in new product launches, including treatments for low testosterone and menopause.
“Investment in the platform and in technology like artificial intelligence, as well as expansion abroad, would play a bigger role for the company this year.”
The Weight-Loss Drug Dilemma
Hims & Hers’ involvement in the weight-loss drug market, particularly its launch of a compounded version of Wegovy, has attracted increased scrutiny. Novo Nordisk (NVO), the maker of Wegovy, initiated legal action against Hims & Hers, and the U.S. Department of Health and Human Services referred the company to the Justice Department for potential legal violations. Consequently, Hims & Hers halted the sale of the compounded Wegovy product after engaging in discussions with industry stakeholders.
Despite the challenges in the weight-loss sector, Hims & Hers emphasizes that the majority of its sales and profits originate from other areas of its business. The company recently announced its acquisition of Australia-based telehealth provider Eucalyptus for $1.15 billion, signaling its commitment to global expansion. For more related Finance news, explore our archives.
Focus on Hims Hers Profits
The focus on Hims Hers profits stems from the delicate balance between investing in growth initiatives and maintaining profitability. The company’s aggressive marketing campaigns, technological investments, and international expansion plans require substantial capital, which can strain short-term earnings. While the long-term vision remains promising, investors are closely monitoring the company’s ability to navigate regulatory hurdles and achieve sustainable profitability.
The midpoint of Hims & Hers’ full-year sales forecast, ranging from $2.7 billion to $2.9 billion, exceeded Wall Street’s estimates. However, the market’s immediate reaction reflects a preference for tangible earnings over potential future growth, particularly in light of the regulatory headwinds facing the company’s weight-loss drug business.
Looking Ahead for HIMS
The coming quarters will be crucial for Hims & Hers as it seeks to demonstrate its ability to manage costs, navigate regulatory challenges, and achieve its ambitious growth targets. The company’s success will depend on its ability to diversify its revenue streams, effectively manage its marketing spend, and maintain a strong reputation in the face of increased scrutiny.
Source: MarketWatch
